We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Molecular Probes Licenses Fluorescence Technology to LightUp

By HospiMedica staff writers
Posted on 24 Apr 2003
New DNA typing assays using fluorescence-based technology licensed from Molecular Probes (Eugene, OR, USA) are being launched by LightUp Technologies AB (Huddinge, Sweden).

These new assays, called LightUp Probes, can be used to identify and quantify the presence of bacteria, viruses, and other pathogens by detecting and analyzing DNA. Molecular Probes will supply advanced fluorescent stains for the assays that increase sensitivity in detecting DNA and other nucleic acids. The LightUp Probes are short peptide nucleic acid conjugates that increase in fluorescence when hybridized to target sequences. The technology is useful for identifying and quantifying targets in an extremely rapid, one-step homogenous hybridization assay. It can be used on its own or in combination with polymerase chain reaction (PCR).

"The combination of our innovative DNA typing technology and Molecular Probes' proprietary fluorescent stains is truly synergistic,” said Ulrica Sehlstedt, Ph.D., CEO of LightUp Technologies. "When enhanced with Molecular Probes' fluorescent stains, our LightUp Probes make DNA assays, including those using real-time PCR, even more sensitive, enabling their use in a wide variety of applications.”




Related Links:
Molecular Probes
LightUp Technologies

New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Online QC Software
Acusera 24•7
New
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Thyroid Test
Anti-Thyroid EIA Test

Latest Industry News

Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases
24 Apr 2003  |   Industry

Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
24 Apr 2003  |   Industry

Bruker Expands NGS Capabilities for Sepsis and Bloodstream Infections
24 Apr 2003  |   Industry



PURITAN MEDICAL